Primecap Management Co. CA acquired a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 677,872 shares of the medical technology company's stock, valued at approximately $213,421,000. Primecap Management Co. CA owned 0.18% of Stryker at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of SYK. Gables Capital Management Inc. purchased a new position in Stryker during the 2nd quarter worth $25,000. Kilter Group LLC bought a new stake in Stryker during the 2nd quarter valued at $25,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the 4th quarter worth $26,000. Sankala Group LLC purchased a new stake in shares of Stryker in the 4th quarter worth $26,000. Finally, Compass Financial Management LLC bought a new position in shares of Stryker during the 2nd quarter worth $27,000. 77.09% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on SYK. Weiss Ratings reiterated a "hold (c)" rating on shares of Stryker in a report on Friday, July 31st. Royal Bank Of Canada dropped their price objective on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. Leerink Partners reduced their price objective on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating for the company in a research note on Friday, June 5th. Finally, Wolfe Research lowered Stryker from an "outperform" rating to a "peer perform" rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and an average price target of $386.28.
Get Our Latest Stock Analysis on Stryker
Insiders Place Their Bets
In other news, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of the business's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 355,370 shares of company stock valued at $119,447,201. Insiders own 4.60% of the company's stock.
Stryker Trading Up 1.0%
Shares of NYSE:SYK opened at $331.06 on Wednesday. The business's 50-day moving average is $327.80 and its 200 day moving average is $331.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm has a market capitalization of $126.98 billion, a P/E ratio of 34.31, a P/E/G ratio of 2.09 and a beta of 0.76.
Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter last year, the company earned $3.13 earnings per share. The company's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker's dividend payout ratio (DPR) is 36.48%.
About Stryker
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.